×

DBV Technologies : Largest Presence Ever of DBV Technologies at 2015 Allergy Meeting

  • Six Presentations Highlighting the Potential of Epicutaneous Immunotherapy (EPIT®) in the Treatment of Food Allergies
  • Late-Breaking Oral Presentation by Pr. Hugh Sampson on VIPES results
  • Keynote Oral Presentation by Pr. Christophe Dupont on EPIT®

Bagneux, France, Feb. 3, 2015 (GLOBE NEWSWIRE) -- DBV Technologies, (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage specialty biopharmaceutical company, today announced that six abstracts on Epicutanous Immunotherapy (EPIT®) were selected for presentation at the 2015 American Academy of Allergy, Asthma & Immunology (AAAAI; http://annualmeeting.aaaai.org/) Annual Meeting in Houston, Texas, February 20-24, 2015. The presentations will include detailed results from the Phase 2b trial of Viaskin® Peanut, as well as key preclinical data on EPIT's mechanism of action.

The abstracts will also be published in the February 2015 supplement of the Journal of Allergy and Clinical Immunology (JACI). All abstracts are available online at http://www.jacionline.org/.

On February 24th at 5pm CST, DBV be will providing an investor and analyst briefing in Houston, Texas. This event will be webcasted live. Details for this event will be posted on the DBV website at www.dbv-technologies.com.

Title Epicutaneous Immunotherapy (EPIT®) Is Effective and Safe to Treat Peanut Allergy:
A Multi-National Double-Blind Placebo-Controlled Randomized Phase IIb Trial
Date February 24 - 2:00 pm to 3:15pm
Presenter Pr. Hugh A. Sampson from Kurt Hirschhorn Professor of Pediatrics, Director of the Jaffe Food Allergy Institute and Dean of Translational Biomedical Science at The Mount Sinai Medical Center in New York (USA)
Session Name Food Allergy, Innate Immunity and Genetics of Atopic Dermatitis
Session Poster Number: L28, Session Number: 5611
Link http://www.jacionline.org/article/S0091-6749%2814%2903701-4/fulltext
Type of Session Late Breaking Oral Abstract Session
Title EPIT® for Food Allergy as an Alternative Pathway for Oral Tolerance Induction
Date February 21 - 4:45 pm to 6:00 pm
Presenter Pr. Christophe Dupont, Head of the Pediatric-Gastroenterology Ambulatory Department at Necker Hospital, Paris, France
Session Food Immunotherapy: What is the Best Method?
Type of Session Oral Presentation
Location Convention Center, Level Three, General Assembly Theater A
Title Larger and Stronger Expression of Tregs Gut Homing Receptors with EPIT than with Sublingual or Oral Immunotherapy
Date February 22 - 3:15 pm to 3:30 pm
Presenter Dr. Vincent Dioszeghy, Researcher at DBV Technologies
Session Name Peptide and Epicutaneous Immunotherapy
Session Poster Number: 518, Session Number: 3606
Type of Session Oral poster session

Title Epicutaneous Immunotherapy Prevents from Induction of Anaphylaxis to Further Allergen
Date February 22 - 9:45am to 10:45am
Presenter Dr. Lucie Mondoulet, Head of Research at DBV Technologies
Session Name Peptide and Epicutaneous Immunotherapy
Session Number: 467, Session Number: 3212
Type of Session Poster Session
Tittle Epigenetic Changes Following Epicutaneous Immunotherapy in Peanut Sensitized Mice
Date Sunday, February 22, 2015 between 9:45am to 10:45am
Presenter Dr. Lucie Mondoulet
Session Name Peptide and Epicutaneous Immunotherapy
Session Number: 466, Session Number: 3212
Type of Session Poster Session
Tittle Epicutaneous but Not Oral Immunotherapy Induces Antigen-Specific Gastrointestinal Tregs and Protects Against Food-Induced Anaphylaxis
Date Monday, February 23, 2015 between: 9:45am to 10:45am
Presenter Dr. Leticia Tordesillas from Icahn School of Medicine at Mount Sinai, Jaffe Food Allergy Institute, New York, USA
Session Name Mechanisms of T Cells and Signaling in Disease
Session Number: 732, Session Number: 4211
Type of Session Poster Session

About DBV Technologies

DBV Technologies is developing Viaskin®, an innovative new approach to the treatment of allergies - a major public health issue that has been increasing in prevalence. DBV Technologies, incorporated in France in 2002, has developed a proprietary, worldwide-patented technology for administering an allergen to intact skin while avoiding transfer to the blood, and thus considerably lowering the risk of a systemic, allergic reaction in the event of accidental exposure. DBV Technologies is focusing on food allergies, including milk and peanut, for which there are currently no effective treatments. DBV Technologies has designed two products candidates: Viaskin® Peanut and Viaskin® Milk. The clinical development program for Viaskin® Peanut has received Fast Track designation from the US Food and Drug Administration.

DBV Technologies shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and on the Nasdaq Stock Market in the form of American Depositary Shares (each representing one-half of one ordinary share) (Ticker: DBVT). For more information on DBV Technologies, please visit our website: www.dbv-technologies.com

Forward Looking Statements

This press release contains forward-looking statements, including statements about the safety and efficacy of Epicutenaous Immunotherapy (EPIT) via Viaskin, including the potential to prevent sensitizations in other allergens, the potential to induce a sustained protection effect and the potential to influence the natural history of allergy. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. In particular it should be noted that these data are preclinical in nature and have not been demonstrated in human subjects. The company's product candidates have not been approved for sale in any jurisdiction. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, the risk that historical preclinical results may not be predictive of future clinical trial results, and the risk that historical clinical trial results may not be predictive of future trial results. A further list and description of these risks, uncertainties and other risks can be found in the Company's regulatory filings with the French Autorité des Marchés Financiers, the Company's Securities and Exchange Commission filings and reports, including in the Company's prospectus filed with the SEC on October 22, 2014 and future filings and reports by the Company. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. DBV Technologies undertakes no obligation to update or revise the information contained in this Press Release, whether as a result of new information, future events or circumstances or otherwise.

DBV Technologies Contacts

Susanna Mesa
VP Finance, US Investor Relations & Strategy

Tel. : +1 917-346-3447

susanna.mesa@dbv-technologies.com



DBV IR and Media Contacts
Nathalie Donne
Director, Corporate Communication & Business Development

Tel. : +33(0)1 55 42 78 72

nathalie.donne@dbv-technologies.com
Marion Janic
US Media Relations

Rooney & Associates

Tel. : +1-212-223-4017

mjanic@rooneyco.com

DBV to attend AAAAI http://hugin.info/156437/R/1891497/669804.pdf

HUG#1891497

Source: DBV Technologies